These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 12362228)

  • 1. Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?
    Oger E; Lacut K; Le Gal G; Van Dreden P; Bressollette L; Scarabin PY; Leroyer C; Mottier D
    Thromb Haemost; 2002 Oct; 88(4):587-91. PubMed ID: 12362228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis.
    Legnani C; Cini M; Cosmi B; Mattarozzi S; Lo Manto G; Palareti G
    Thromb Haemost; 2004 Apr; 91(4):712-8. PubMed ID: 15045132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
    Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
    Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin generation and activated protein C resistance in the absence of factor V Leiden correlates with the risk of recurrent venous thromboembolism in women aged 18-65 years.
    Sonnevi K; Tchaikovski SN; Holmström M; Rosing J; Bremme K; Lärfars G
    Thromb Haemost; 2011 Nov; 106(5):901-7. PubMed ID: 21947267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential.
    Zotz RB; Gerhardt A; Kluft C; Scharf RE
    Thromb Haemost; 2005 Feb; 93(2):306-10. PubMed ID: 15711747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients.
    Nojima J; Kuratsune H; Suehisa E; Kawasaki T; Machii T; Kitani T; Iwatani Y; Kanakura Y
    Thromb Haemost; 2002 Nov; 88(5):716-22. PubMed ID: 12428083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.
    Folsom AR; Cushman M; Tsai MY; Aleksic N; Heckbert SR; Boland LL; Tsai AW; Yanez ND; Rosamond WD
    Blood; 2002 Apr; 99(8):2720-5. PubMed ID: 11929758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
    Bergrem A; Dahm AE; Jacobsen AF; Mowinckel MC; Sandvik L; Sandset PM
    Br J Haematol; 2011 Jul; 154(2):241-7. PubMed ID: 21564075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
    Rodeghiero F; Tosetto A
    Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers.
    Mingozzi F; Legnani C; Lunghi B; Scanavini D; Castoldi E; Palareti G; Marchetti G; Bernardi F
    Thromb Haemost; 2003 Jun; 89(6):983-9. PubMed ID: 12783110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls.
    Zangari M; Berno T; Zhan F; Boucher KM; Tricot G; Fink L
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):420-3. PubMed ID: 21537162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population.
    Torres JD; Cardona H; Alvarez L; Cardona-Maya W; Castañeda SA; Quintero-Rivera F; Cadavid A; Bedoya G; Tobón L
    Am J Hematol; 2006 Dec; 81(12):933-7. PubMed ID: 16917913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL; Welsh CH; Qamar Z; Marlar RA
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
    Aboud MR; Ma DD
    Clin Lab Haematol; 2001 Dec; 23(6):411-6. PubMed ID: 11843891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Case-control study and meta-analysis.
    Rehak M; Rehak J; Müller M; Faude S; Faude F; Siegemund A; Krcova V; Slavik L; Hasenclever D; Scholz M; Wiedemann P
    Thromb Haemost; 2008 May; 99(5):925-9. PubMed ID: 18449423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
    Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
    J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.